Casa
asdas

A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).

Por um escritor misterioso

Descrição
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients – baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice – topic of
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. - Abstract - Europe PMC
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
THU0379 REDUCTION OF ANTERIOR UVEITIS FLARES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS FOLLOWING ONE YEAR OF TREATMENT WITH CERTOLIZUMAB PEGOL: 48-WEEK INTERIM RESULTS FROM A 96-WEEK OPEN-LABEL STUDY
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
IJMS, Free Full-Text
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
New evidence on the management of spondyloarthritis
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Mean (A) ASDAS and (B) BASDAI up to Week 48. Safety Set (N=89).
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
PDF) Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
POS0229 DISEASE ACTIVITY AND INFLAMMATION FOLLOWING WITHDRAWAL OF CERTOLIZUMAB PEGOL TREATMENT IN AXIAL SPONDYLOARTHRITIS PATIENTS WHO DID NOT EXPERIENCE FLARES DURING THE C-OPTIMISE STUDY
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
/index.php/cjht/article/downlo
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
WO2021067465A1 - Treating spondyloarthritic and psoriatic conditions with upadacitinib - Google Patents
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy - ScienceDirect
de por adulto (o preço varia de acordo com o tamanho do grupo)